NEW YORK (GenomeWeb News) – Shares of Helicos BioSciences climbed 13.1 percent in afternoon trade on the Nasdaq after the firm said that it had taken the first order for its HeliScope next-generation single molecule sequencing platform.
A company spokesperson declined to name the customer who placed the order.
Shares of Helicos were trading at $13.03 this afternoon.
At the JPMorgan Healthcare Conference in early January, Helicos President and COO Steve Lombardi said that interest from potential customers in pharma, academia, and genome centers outnumbered the nine instruments on the firm’s production floor.